Document is current

Article History

Received: 20 February 2024

Accepted: 20 July 2024

First Online: 2 August 2024

Declarations

:

: MMAJ declares consulting or advisory role: Celgene, Sanof, Pfzer, Bristol-Myers Squibb, LEO Pharma, Daiichi Sankyo, Bayer, Halozyme; speakers’ bureau: Rovi; research funding: Sanof, LEO Pharma and patents, royalties, other intellectual property: risk assessment model in venous thromboembolism in patients with cancer. OML has participated as speaker in meetings sponsored by Leo Pharma, Rovi, Menarivi, Servier. MM reports honoraria from SeaGen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, Roche; consulting fees from Roche, Novartis, AstraZeneca, Daiichi Sankyo, SeaGen, Lilly, Sanofi; advisory board of Novartis and holds leadership roles in GEICAM (Board of Directors), TRIO. LJC, GA, JDS, SAJ, CVJL, BAC and MB declare no conflict of interests.

: The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial.

: Signed informed consent was obtained from all the patients.